Double-Blinded, Vehicle-Controlled Proof of Concept Study to Investigate the Recurrence of Inflammatory and Noninflammatory Acne Lesions Using Tretinoin Gel (Microsphere) 0.04% in Male Patients after Oral Isotretinoin Use by Vender, Reid & Vender, Ronald
Hindawi Publishing Corporation
Dermatology Research and Practice
Volume 2012, Article ID 736532, 5 pages
doi:10.1155/2012/736532
Clinical Study
Double-Blinded,Vehicle-ControlledProof of ConceptStudy to
Investigate the Recurrenceof Inﬂammatory and
NoninﬂammatoryAcneLesionsUsingTretinoinGel
(Microsphere) 0.04% in Male Patients after Oral Isotretinoin Use
Reid Vender1 and Ronald Vender1,2
1Dermatrials Research, 132 Young Street Hamilton, ON, Canada L8N 1V6
2Division of Dermatology, Department of Medicine, McMaster University, Hamilton, ON, Canada L85 4L8
Correspondence should be addressed to Ronald Vender, ron.vender@me.com
Received 24 January 2012; Accepted 26 February 2012
Academic Editor: Craig G. Burkhart
Copyright © 2012 R. Vender and R. Vender. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background. Although isotretinoin orally is commonly used for moderate to severe or scarring acne, it is not a cure. Unfortunately
recurrence is unpredictable and varies within the acne population. Objectives. Using a proof of concept study, determine the
recurrence of acne after isotretinoin use in male patients. Methods. Twenty males aged 18–45 years old were enrolled. Subjects
successfully completed a treatment of acne vulgaris with oral isotretinoin (120–150mg/kg/course). Subjects were randomized 1 to
1. The study duration was 24 weeks. The primary endpoint measured was the absolute change in lesion counts from baseline to
weeks 16 and 24. Local tolerability assessments were measured. Results. There were favorable changes in all outcomes measured.
Overall, there was a 38.7% lower lesion count with tretinoin 0.04% microsphere gel use versus vehicle. The active product was
well tolerated with great patient satisfaction. There were no signiﬁcant safety issues. The limitations included the low number of




Acne is a common dermatological disorder that aﬀects mil-
lions of North American adolescents and young adults. Al-
though isotretinoin orally is commonly used for moderate to
severe or scarring acne, it is not a cure. Even postisotretinoin
acne can recur. The use of topical retinoids is part of basic
and early acne treatment to treat comedonal noninﬂam-
matory acne lesions and occasional inﬂammatory lesions.
After oral isotretinoin, it is not uncommon for comedones
as well as noninﬂammatory and inﬂammatory papules to
recur. Unfortunately this is unpredictable and varies within
the acne population. Despite this, there has been no formal
study to look at the prevention of recurrence of these acne
lesions after isotretinoin. This information may enhance the
therapeutic options for postisotretinoin patients in order to
prevent recurrence of their disease. The study product was
tretinoin 0.04% gel (microsphere) indicated for the topical
treatment of acne vulgaris.
2.MaterialsandMethods
2.1. Study Design. This was a double-blinded vehicle con-
trolled proof of concept study with an enrollment of 20 male
subjects. Subjects were randomized 1:1 to study product or
vehicle.Subjectswererandomlyassignedtoeachgroupbyan
unblinded dispenser. The study duration was 24 weeks with
visits at week 0 (baseline), week 4, week 8, week 16, and week
24. All study products were administered once daily (and
left on for a minimum of 8 hours) for 24 weeks. Subjects
applied a suﬃc i e n ta m o u n to fs t u d yp r o d u c tt oc o v e rt h e
entireface.Thestudywasapprovedbyanindependentethics2 Dermatology Research and Practice
Table 1: Investigator’s Static Global Assessment.
Investigator’s Static Global Assessment
0: clear skin with no inﬂammatory or noninﬂammatory lesions
1: almost clear: rare noninﬂammatory lesions with no more than rare papules
2: mild severity: greater than Grade 1, some noninﬂammatory lesions with no more than a few inﬂammatory lesions (papules/pustules
only, no nodular lesions)
3: moderate severity: greater than Grade 2, up to many noninﬂammatory lesions and may have some inﬂammatory lesions, but no more
than one small nodular lesion
4: severe: greater than Grade 3, up to many noninﬂammatory and inﬂammatory lesions, but no more than a few nodular lesions
5: very severe: many noninﬂammatory and inﬂammatory lesions and more than a few nodular lesions; may have cystic lesions
Table 2: Subject’s Global Assessment.
SGA Assessment Scale
0: my face is basically free of acne, with only an occasional blackhead and/or whitehead
1: my face has several blackheads and/or whiteheads and small pimples but there are no tender deep-seated bumps or cysts
2: my face has several to many blackheads and/or whiteheads and small- to medium-sized pimples, and may have one deep-seated bump or
cyst
3: my face has many blackheads and/or whiteheads, many medium- to large-sized pimples, and perhaps a few deep-seated bumps or cysts
4: my face has blackheads and/or whiteheads, several to many medium- to large-sized pimples, and deep-seated bumps or cysts dominate
Table 3: Local tolerability assessments.
Grade Subject-assessed itching and
burning/stinging
0 None Normal, no discomfort
1S l i g h t A noticeable discomfort that causes
intermittent awareness
2M o d e r a t e
A noticeable discomfort that causes
intermittent awareness and interferes
occasionally with normal daily activities
3S t r o n g A deﬁnite continuous discomfort that
interferes with normal daily activities
reviewboard.Theprimaryobjectivewastoassesstheeﬃcacy
of tretinoin 0.04% gel (microsphere) on the recurrence rate
of acne after isotretinoin use compared to vehicle. The sec-
ondary objective was to assess the safety and tolerance of
tretinoin 0.04% gel (microsphere) after isotretinoin use.
The following information was collected at each visit in
the study: medical history/review of systems, concomitant
medications query, adverse events, lesion counts, Investiga-
tor’sStaticGlobalAssessment(ISGA)(Table 1),andSubject’s
Global Assessment (SGA) (Table 2), and local tolerability
assessments by the investigator (LTA) and subject (SALT)
were also determined (Tables 3 and 4). The lesion counts
were carried out by a blinded physician (dermatologist)
trained and experienced in acne lesion counting and rat-
ing. Any missing data for subjects were imputated as in-
tent to treat (iTT) and last observation carried forward
(LOCF). Simple statistical methods were used. Poisson 95%
Conﬁdence intervals were calculated using the Northwest
Public Health Observatory Small Area Database Excel down-
load program. (http://www.nwpho.org.uk/sadb/). The lesion
count, ISGA, SGA, LTA, and SALT values were calculated
using the mean of all values for that visit for all patients with
LOCF.
3. Inclusion and Exclusion Criteria
3.1. Inclusion Criteria. Subjects were males aged between 18
and 45 years old who had successfully completed a treat-
ment of acne with oral isotretinoin (minimum 4 months/
maximum 6 months with an average of 5 months and a total
of 120–150mg/kg/course), could attend scheduled study
follow-up visits at the outpatient dermatology clinic, agreed
to informed consent for participation in a study, and agreed
to comply with the treatment and follow up procedures.
3.2. Exclusion Criteria. Subjects meeting any of the fol-
lowing criteria were not be eligible for study admission:
subjects who received isotretinoin for conditions other than
acne vulgaris, subjects who had been oﬀ isotretinoin for
less than 30 days (so the immediate beneﬁcial eﬀects of
isotretinoin would be mostly gone) or more than 90 days
(to try to capture recurrence of acne before the beneﬁts
of isotretinoin would be completely gone) at the time of
enrollment of the study, subjects who had used prescription
topical acne treatment (tretinoin, benzoyl peroxide (BPO),
topical antibiotics, or any combination products) between
the end of therapy of isotretinoin within 2 weeks of study
enrollment or oral antibiotics of any type between the
end of therapy of isotretinoin within 4 weeks of study
enrollment and throughout the study, subjects who had been
previously diagnosed with an endocrinologic disorder likely
to cause acne such as genital/adrenal hyperplasia, adrenal
tumors, or any other hypoandrogenic state, subjects who
are used any systemic medications likely to cause or abate
acne such as oral phenytoin or any other epileptic, ﬁnas-
teride, spironolactone, or ﬂutamide, testosterone, or dietaryDermatology Research and Practice 3
Table 4: Local tolerability assessments.
Evaluator-assessed erythema, dryness, and peeling
Grade Severity Erythema Dryness Peeling
0 Absent No redness None No peeling
1S l i g h t Faint red or pink coloration, barely
perceptible
Barely perceptible dryness with no
ﬂakes or ﬁssure formation Mild localized peeling
2 Mild Light red or pink coloration Easily perceptible dryness with no
ﬂakes or ﬁssure formation Mild and diﬀuse peeling
3 Moderate Medium red coloration Easily noted dryness and ﬂakes but no
ﬁssure formation Moderate and diﬀuse peeling
4 Severe Beet red coloration Easily noted dryness with ﬂakes and
ﬁssure formation
Moderate to prominent, dense
peeling
body-building protein powders, and subjects who used
topical corticosteroids on the face or systemic corticosteroids
within the past 4 weeks. Subjects who used inhaled, intraar-
ticular, or intra-lesional steroids other than for facial acne
were acceptable.
Also excluded were subjects who currently used any
medicationthatintheopinionoftheinvestigatorcouldaﬀect
the action or evaluation of the study product or place the
subject at undue risk. The use of abradants, facials, and peels
containing glycolic or other acids; masks, washes, or soaps
containing BPO, salicylic acid, or sulfacetamide sodium;
nonmild facial abradants, facials, peels containing glycolic or
otheracids;masks,washes,orsoapscontainingBPO,salicylic
acid,orsulfacetamidesodium;non-mildfacialcleansers;and
moisturizers that contained retinol, salicylic acid, or α-o rβ-
hydroxy acids within the past 2 weeks of randomization and
throughout the duration of the study was prohibited.
Also prohibited was planned use of medications that
are reported to exacerbate acne (e.g., megadoses of certain
vitamins, such as vitamin D (>2000IU per day) and vitamin
B12 (>1mg/day), haloperidol, halogens (e.g., iodide and
bromide), lithium, hydantoin, and phenobarbital, because
these could also impact eﬃcacy assessments. Subjects who
planned to use multivitamins (without vitamin A), iron sup-
plements, and folate were acceptable.
Subjects were excluded that had a facial procedure (such
as chemical or laser peel, microdermabrasion, blue light
treatment, etc.) performed by an esthetician, beautician,
physician, nurse, or other practitioner, within the past 4
weeks or planned to be performed during the conduct of the
study. If subjects had a known hypersensitivity or have had
previous allergic reaction to any of the active components
or excipients of the study product, used any investigational
therapy within 4 weeks of randomization, or were currently
participating in another clinical study, currently abusing
drugsoralcohol(drugscreeningwasnotrequired),hadasig-
niﬁcant medical history of being immunocompromised, had
other conditions that, in the judgment of the investigator,
would put the subject at unacceptable risk for participation
in the study, had any major illness within 30 days before
the screening examination, were current employees of the
investigator or sponsor involved in the study, or were
an immediate family member (partner, oﬀspring, parents,
Table 5: Patient demographics.
Characteristic Active Vehicle
Number of subjects (n)1 0 1 0
Gender 100% male 100% male
Mean age (range) 21 years old (18–29) 22.4 years old
(18–42)
Race 90% Caucasian 80%
Caucasian
Duration of acne (range) 5.2 yrs (1–14) 5.6 yrs (2–11)
siblings,orsibling’soﬀspring)ofanemployeeinvolvedinthe
study, they were also excluded.
4. Study DrugAdministration
Detailed instructions concerning protocol requirements and
applicationofthestudyproductwereprovidedtothesubject.
The study products (active and vehicle) were provided in
unlabeled grey plastic 50g pump dispensers. A moisturizer
and cleanser provided were the only other products allowed
to be used on the face during the duration of the study.
The moisturizer was a noncomedogenic, water-based facial
moisturizer that was lightweight and nongreasy as well as
hypoallergenic,fragrance-free,and alcohol-free (Neutrogena
Moisture Oil-Free, Johnson & Johnson, Montreal, Canada).
The cleanser was soap-free and alcohol-free as well as
noncomedogenic and hypoallergenic (Neutrogena Fresh
Foaming Cleanser, Johnson & Johnson, Montreal, Canada).
The subject was instructed to wash their face ﬁrst and allow
the areas to fully dry for approximately 20 to 30 min-
utes before applying study product. Subjects were verbally
instructedtoapplyasuﬃcientamount(twopea-sizeddrops)
of study product to cover the entire face (including the
forehead, nose, cheeks, and chin). Subjects were instructed
to consistently apply study product either in the morning or
in the evening throughout the 24 weeks of the study.
5. Results
The patient’s characteristics in the active and vehicle groups
were similar as seen in Table 5.4 Dermatology Research and Practice
Table 6: Mean lesion counts.
Lesion Baseline Week 4 Week 8 Week 16 Week 24
Active (95% CI) 0 (0, 0.369) 0.5 (0, 0.467) 2.1 (0.024, 0.722) 2.1 (0.024, 0.722) 1.2 (0.003, 0.557)
Vehicle (95% CI) 0 (0, 0.369) 1.9 (0.011, 0.642) 2.6 (0.042, 0.801) 2.7 (0.042, 0.801) 3.1 (0.062, 0.877)
Table 7: Mean Investigator’s Static Global Assessment.
ISGA Baseline Week 4 Week 8 Week 16 Week 24
Active (range) 0 (0) 0.1 (0-1) 0.3 (0-1) 0.43 (0-1) 0.33 (0-1)
Vehicle (range) 0 (0) 0.3 (0.1) 0.5 (0-1) 0.43 (0-1) 0.33 (0-1)
Table 8: Mean Subject’s Global Assessment.
SGA Baseline Week 4 Week 8 Week 16 Week 24
Active (Range) 0 (0) 0.13 (0-1) 0.13 (0-1) 0.43 (0-1) 0.13 (0-1)
Vehicle (Range) 0.13 (0-1) 0.33 (0-1) 0.33 (0-1) 0.33 (0-1) 0.33 (0-1)
Table 9: Mean Local Tolerability Assessments (LTA) (Investigator).
LTA Baseline Week 4 Week 8 Week 16 Week 24
Active (Range) 0 (0) 0.6 (0–3) 0.2 (0–2) 0.4 (0–4) 0.3 (0-1)
Vehicle (Range) 0 (0) 0.1 (0-1) 0.1 (0-1) 0.3 (0–2) 0.2 (0–2)
The average lesion counts for the active and vehicle
groups are presented in Table 6. Compared to vehicle the
active group provided a 38.7% lower lesion count.
Overall, during the study period, the ISGA favored the
active ingredient with a lower average grade of acne (a more
favorable response) (see Table 7), except at week 24 where no
diﬀerence was noted.
TheSGAcorrelatedwellwiththeISGAandagainseemed
to favor the active group (Table 8) with a score two levels
lower than that of the vehicle group.
D u et ot h es m a l ln u m b e ro fp a t i e n t si ti sd i ﬃcult to
assess the true statistical signiﬁcance of trend toward the
appearance of clinical eﬃcacy of tretinoin compared to
vehicle. It seems that one can state that there appears to be
ad i ﬀerence.
Overall there were no serious adverse events during the
study. There were no adverse events reported during the
study either. This may be due to the age of the patients
participating in the study that may be reluctant to complain
despite direct questioning. Both the active ingredient and
vehicle were well tolerated and no treatment was interrupted
due to any local tolerability complaints or local side eﬀects.
There was only a minimal diﬀerence local tolerability score
of 0.2 in the vehicle group compared to the active group
(range 0–4). The assessments of both the investigator (LTA)
and subjects (SALT) correlated well. See Tables 9 and 10.
The total number of missed applications per course of six
months of the study averaged 4.4 for the active group (range
0–10) and 3.8 for the vehicle group (range 0–18). For this
patient population the averaged missing is only 2.4% and
2.1% of the total possible applications during the six-month
studyperiod.Unfortunatelythreeoftheactivegrouppatients
and two of the vehicle group patients were lost to follow-up
Table 10: Mean Subject’s Local Tolerability Assessments (SALT).
SALT Baseline Week 4 Week 8 Week 16 Week 24
Active
(range) 0 (0) 0.23 (0-1) 0.23 (0-1) 0 (0) 0.13 (0-1)
Vehicle
(range) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
at various points in the study but their data was imputed as
intenttotreatwithlastobservationcarriedforward.Thiswas
a loss of a quarter of the patients.
6. Discussion
Acne is a common dermatological disorder that peaks at the
a g eo f1 8a n dc a na ﬀect most adolescents as stated by Nigh-
land and Grossman [1].
Topical retinoids such as tretinoin and adapalene have
been clinically proven to be eﬃcacious in mild to moderate
cases but severe acne often requires systemic medications
such as antibiotics or oral isotretinoin.
Oral isotretinoin has been established to be an eﬀective
treatment for severe acne over the past two decades as re-
ported by Wysowski et al. [2] .T h er e c u rr e n c eo fa c n eo ra c n e
relapse after isotretinoin usage has not been well studied.
The prevention of acne after oral isotretinoin has not been
studied until this proof of concept study was established.
Azoulay et al. [3, 4] reported that a Canadian-nested case-
control study of 17,351 ﬁrst time isotretinoin users revealed
that 7100 (41%) of subjects experienced a relapse of acne
requiring an antiacne medication (isotretinoin or other).
Twenty-six percent of these relapse patients did requireDermatology Research and Practice 5
a second course of isotretinoin within approximately two
years after the end of their ﬁrst treatment. Twenty percent of
theacnerelapsepatientsonlyrequiredtopicaltreatment.The
factors associated with these recurrences were male patients
under 16 years of age, living in an urban area and low
cumulative dose under 2450mg over ﬁve months. This low-
dose was only in 25% of the population-based cohort in the
general medical providers as reported by Azoulay et al. [3, 4].
The number of acne relapse patients in the low dose group
was not provided.
Layton et al. [5, 6] reported a similar relapse rate of
39% of isotretinoin patients (n = 34) with the highest re-
lapsers in those patients receiving a cumulative dose of
less than 120mg/kg per course. The average age was 20.8
years. Twenty-one percent of these patients required topical
therapy alone. Seventy-eight percent of the relapse occurred
in the ﬁrst 18 months. Twenty percent of the relapsers were
predominantly facial acne. This study studied only facial
acne.
Stainforth et al. [7] reported that in their group of 299
patients, 22.7% required repeat courses of treatment. Some
of these were for relapse or partial response and a small
proportion for psychological reasons. It is not known what
the actual relapse rate of acne was as the paper dealt with
the factors predicting the need for more than one course of
isotretinoin. Their patients had predominantly facial acne.
Therefore reports of acne relapse range from 21 to 41%
by Azoulay [3, 4], Layton [5, 6], Chivot [8], White [9],
and their coauthors. However there are no reports on the
prevention of these potential relapse after isotretinoin. This
study was a proof of concept to determine whether acne
could be prevented in an adult male population after a single
course of isotretinoin. Overall the results favored tretinoin
0.04% microsphere gel in the prevention of recurrent acne
compared to vehicle over a period of six months.
Overall there was a trend to the eﬃcacy of tretinoin
0.04% microsphere gel to the prevention of recurrent acne
after isotretinoin use in male patients over 18 years old
over a six-month period. A 38.7% lower lesion count was
observed in the tretinoin 0.04% microsphere gel group. The
discrepancy between the lesion count scores and the ISGA
assessment at week 24 can be explained by the fact that the
ISGA is an overall global assessment and is performed before
the lesion counts as not to bias the evaluator.
T h ea c t i v ep r o d u c tw a sw e l lt o l e r a t e dw i t hg r e a tp a t i e n t
satisfaction that correlated well between the investigator’s
and subject’s assessment of tolerability with only 0.2 point
diﬀerence.
Thestrengthsofthisstudypresentedarethefactsthatthe
patients were all treated similarly with a course of 120mg/kg
over ﬁve months, all were males over eighteen years of age,
all were treated by the same dermatologist, and all were from
urban areas. The patients had previously not required one or
two courses of isotretinoin.
The weakness of this study is the low number of patients
enrolled, the average age of the patients, the percentage of
patients lost to follow-up, the male predominance, and pos-
sible the short duration of preventative use of the study
agent after isotretinoin (six months). Larger and longer
follow-up studies are required (ClinicalTrials.Gov Identiﬁer:
NCT00939133).
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